The Manila Times1h
INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer
The Scientific Review Committee (SRC) charter is to review the safety data from the patients treated in the Phase I portion ...
INmune Bio, Inc.: INmune Bio Opens Phase II in High Dose Cohort of INKmune Trial in Prostate Cancer
Medical review of Phase 1 cohorts demonstrated no safety issuesData to be presented at the 10th Annual Innate Killer Summit, March 3-5 BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) -- INmune Bio ...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences
On June 2, 2024, Caribou issued a press release announcing that it had "presented updated clinical data from the ongoing ...
Morningstar10d
CRBU Investors Have Opportunity to Lead Caribou Biosciences, Inc. Securities Fraud Lawsuit
So what: If you purchased Caribou securities during the ... including preclinical research activities associated with the allogeneic CAR-NK platform; (3) the foregoing was likely to have a ...
Le Lézard6d
Investors who lost money on Caribou Biosciences, Inc.(CRBU) should contact The Gross Law Firm about pending Class Action - CRBU
The Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. . Shareholders who purchased shares ...
Le Lézard8d
CRBU Stock News: Robbins LLP Reminds Investors of the Pending Lead Plaintiff Deadline in the Caribou Biosciences, Inc. Class Action
Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Caribou Biosciences, Inc. securities between July 14, 2023 and ...
Nkarta, Inc. (NASDAQ:NKTX) Receives Consensus Recommendation of “Buy” from Analysts
Shares of Nkarta, Inc. (NASDAQ:NKTX – Get Free Report) have been assigned a consensus rating of “Buy” from the seven ...